Investigators showed that human primary T cells could be activated, transduced, and expanded to high densities in a 2 ml automated closed-system microfluidic bioreactor to produce viable anti-CD19 CAR T cells.
[Nature Biomedical Engineering]
Home Newsletters Cell Therapy News A High-Density Microfluidic Bioreactor for the Automated Manufacturing of CAR T Cells
